Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biomea Fusion Inc
(NQ:
BMEA
)
7.080
-0.530 (-6.96%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Biomea Fusion Inc
< Previous
1
2
3
Next >
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes
December 14, 2022
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date
December 12, 2022
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Is Ardelyx is A Buy After Slip in Early 2022
November 21, 2022
Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them
Via
MarketBeat
Exposures
Product Safety
Biomea Fusion to Participate in Piper Sandler 34th Annual Healthcare Conference
November 11, 2022
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Reports Third Quarter 2022 Financial Results and Business Highlights
November 07, 2022
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion to Present Preclinical Data for BMF-500, an Investigational Oral Covalent FLT3 Inhibitor, at the 64th American Society of Hematology (ASH) Annual Meeting
November 03, 2022
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219
October 31, 2022
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Announces First Patient Dosed with Chronic Lymphocytic Leukemia (CLL) in COVALENT-101 Trial
October 27, 2022
From
Biomea Fusion, Inc.
Via
GlobeNewswire
BMF-219 Enters the Clinic for KRAS Solid Tumors
October 14, 2022
From
Biomea Fusion, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.